CANCER GENE THERAPY

Scope & Guideline

Driving Progress in Molecular Biology for Cancer Solutions

Introduction

Welcome to your portal for understanding CANCER GENE THERAPY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN0929-1903
PublisherSPRINGERNATURE
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1994 to 2024
AbbreviationCANCER GENE THER / Cancer Gene Ther.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'CANCER GENE THERAPY' is dedicated to advancing the field of cancer research through gene therapy approaches. It covers a wide spectrum of topics related to genetic and epigenetic mechanisms underlying cancer, innovative therapeutic strategies, and the evaluation of novel gene therapy applications.
  1. Gene Therapy Innovations:
    Focus on the development and application of various gene therapy techniques, including oncolytic viruses, CAR-T cell therapies, and RNA-based therapeutics.
  2. Molecular Mechanisms and Pathways:
    In-depth exploration of the molecular pathways involved in cancer progression, treatment resistance, and the role of genetic modifications.
  3. Tumor Microenvironment Interactions:
    Investigation of how the tumor microenvironment influences cancer progression and response to therapies, including the role of extracellular vesicles and immune cells.
  4. Biomarker Discovery and Validation:
    Identification and validation of biomarkers for cancer diagnosis, prognosis, and therapeutic response, facilitating personalized medicine approaches.
  5. Translational Research:
    Emphasis on translating laboratory findings into clinical applications, including clinical trials of gene therapy techniques and their effectiveness in cancer treatment.
Recent publications indicate a dynamic evolution in the focus areas of 'CANCER GENE THERAPY', with several themes gaining traction and reflecting the current trends in cancer research.
  1. RNA Modifications and Non-coding RNAs:
    Emerging studies highlight the roles of RNA modifications (e.g., m6A) and non-coding RNAs (e.g., circRNAs, lncRNAs) in cancer biology, signaling pathways, and potential therapeutic targets.
  2. Immunotherapy and Tumor Microenvironment Modulation:
    Increased focus on immunotherapy strategies, including CAR-T cell therapies and immune checkpoint inhibitors, as well as the role of the tumor microenvironment in modulating immune responses.
  3. Synthetic Lethality Approaches:
    Research on synthetic lethality is gaining attention, particularly in the context of targeting specific genetic vulnerabilities in cancer cells, offering new therapeutic strategies.
  4. Targeted Therapy Combinations:
    A notable trend towards investigating the efficacy of combination therapies that target multiple pathways or mechanisms simultaneously to overcome resistance and improve patient outcomes.
  5. Personalized and Precision Medicine:
    Research is increasingly oriented towards personalized medicine, emphasizing the need for tailored therapies based on individual genomic and molecular profiles.

Declining or Waning

While the journal continues to explore a broad range of topics, certain research areas have shown a decline in focus or publication frequency, suggesting shifts in research priorities or emerging interests.
  1. Traditional Chemotherapy Approaches:
    Research related to conventional chemotherapy is less frequently addressed, as the field shifts towards targeted therapies and personalized medicine.
  2. Basic Cancer Biology without Therapeutic Focus:
    Studies focusing solely on basic cancer biology without implications for therapeutic development are becoming less prominent in favor of research with direct clinical applications.
  3. Single-Agent Therapies:
    There is a waning interest in studies evaluating single-agent therapies, as combination therapies and multi-targeted approaches are increasingly favored.
  4. Epidemiological Studies:
    Epidemiological research related to cancer incidence and prevalence is less frequently published, with a greater emphasis on mechanistic and therapeutic studies.

Similar Journals

GENE

Unveiling Innovations in Genetics and Medicine
Publisher: ELSEVIERISSN: 0378-1119Frequency: 48 issues/year

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.

CELL RESEARCH

Exploring Innovations in Molecular Biology
Publisher: SPRINGERNATUREISSN: 1001-0602Frequency: 12 issues/year

CELL RESEARCH is a premier peer-reviewed journal dedicated to advancing the field of cell biology and molecular biology, published by SpringerNature. With an impressive impact factor and consistently ranking in the Q1 quartile for both cell biology and molecular biology, this journal serves as a pivotal resource for researchers, professionals, and students seeking to explore the latest discoveries and advancements in cellular mechanisms and their implications for health and disease. Since its inception in 1996, CELL RESEARCH has cultivated a distinguished reputation, currently boasting ranks in the top percentile of Scopus categories, reaffirming its influence and relevance to the scientific community. Although it is not an Open Access journal, its rigorous selection process ensures the publication of high-quality articles that contribute significantly to our understanding of life sciences. For those deeply engaged in the realms of biochemistry, genetics, and molecular biology, CELL RESEARCH is an essential conduit of innovative research and critical insights.

MOLECULAR THERAPY

Empowering breakthroughs in genetics and pharmacology.
Publisher: CELL PRESSISSN: 1525-0016Frequency: 12 issues/year

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

INTERNATIONAL JOURNAL OF HUMAN GENETICS

Empowering Scholars in the Field of Genetics
Publisher: KAMLA-RAJ ENTERPRISESISSN: 0972-3757Frequency: 4 issues/year

INTERNATIONAL JOURNAL OF HUMAN GENETICS is a distinguished publication dedicated to advancing knowledge in the fields of genetics and molecular biology. Published by KAMLA-RAJ ENTERPRISES, this journal explores critical developments and research findings from 2008 to 2016, though its coverage in Scopus has since been discontinued. With an ISSN of 0972-3757 and an E-ISSN of 2456-6330, the journal aimed to foster scholarly dialogue and serve as a resource for researchers, professionals, and students engaged in human genetics. While the journal holds a modest ranking in categories such as Biochemistry and Genetics, it remains a vital source for exploring niche topics within the realm of human genetics. Researchers interested in genetic screening, gene therapy, and clinical genetics will find valuable insights herein. Despite its pause in indexing, the journal continues to contribute to the academic discourse by disseminating critical research that bridges gaps in understanding human genetics.

Advances in Cancer Biology-Metastasis

Illuminating Mechanisms of Metastatic Progression.
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

Oncologie

Elevating oncology research to new heights.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Elevating the standards of cancer research and treatment.
Publisher: BMCISSN: Frequency: 1 issue/year

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

INTERNATIONAL JOURNAL OF ONCOLOGY

Empowering breakthroughs in oncology and patient care.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Molecular Diagnosis & Therapy

Bridging Genetics and Therapeutics
Publisher: ADIS INT LTDISSN: 1177-1062Frequency: 6 issues/year

Molecular Diagnosis & Therapy, published by ADIS INT LTD, is a premier journal dedicated to the cutting-edge fields of genetics, molecular medicine, and pharmacology. With a strong emphasis on the translation of molecular insights into innovative therapeutic strategies, this journal serves as a vital resource for researchers, clinicians, and students aiming to stay at the forefront of medical and scientific advancements. The journal boasts an impressive standing in its categories, holding a Q1 ranking in Genetics, Medicine (miscellaneous), and Pharmacology, alongside a Q2 classification in Molecular Medicine for 2023, reflecting its influential contributions to the scientific community. Indexed in Scopus, it occupies distinct positions in its respective fields, ranked #77 in Genetics and Pharmacology, and #53 in Molecular Medicine, highlighting its robust impact factor and scholarly influence. Although it is not open access, the journal ensures widespread dissemination of valuable research, promoting enhanced understanding of molecular diagnostic techniques and therapeutic interventions. Since its inception in 2001, and continuing through to 2024, Molecular Diagnosis & Therapy remains an essential platform for disseminating vital research findings, fostering academic collaboration, and driving forward the dialogue in molecular diagnostics and treatment methodologies.

EXPERT REVIEWS IN MOLECULAR MEDICINE

Advancing the Frontiers of Molecular Medicine
Publisher: CAMBRIDGE UNIV PRESSISSN: 1462-3994Frequency: 1 issue/year

EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.